glp 1 and amoxicillin Structure-Based Discovery of Orthosteric Non-Peptide GLP-1R Agonists via Integrated Virtual Screening Molecular Dynamics GLP-1 Medications for Weight Loss:

names to watch: Januvia and Galvus The FDA recently approved the first DPP-4 inhibitor, called Januvia, and the agency is expected to approve a second one, Galvus, later this year

2017 Sep-Oct;35 Suppl 107(5):40-46

Among 69,221 propensity-matched patients with IBD, those who had received a GLP-1 RA had a 5-year colorectal cancer incidence of 0.2% compared with 0.42% in non-GLP-1 RA users (OR, 0.49), corresponding to a 51% reduction in odds of developing colorectal cancer

Janssen K, Mensink RP, Cox FJ, et al

Using Savings Programs and Shopping Smart Manufacturer savings cards and pharmacy discount programs can substantially lower out-of-pocket costs